6RRC

Crystal structure of the N-terminal region of human cohesin subunit STAG1 in complex with RAD21 peptide


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.37 Å
  • R-Value Free: 0.248 
  • R-Value Work: 0.214 
  • R-Value Observed: 0.215 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

STAG1 vulnerabilities for exploiting cohesin synthetic lethality in STAG2-deficient cancers.

van der Lelij, P.Newman, J.A.Lieb, S.Jude, J.Katis, V.Hoffmann, T.Hinterndorfer, M.Bader, G.Kraut, N.Pearson, M.A.Peters, J.M.Zuber, J.Gileadi, O.Petronczki, M.

(2020) Life Sci Alliance 3

  • DOI: 10.26508/lsa.202000725
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • The cohesin subunit STAG2 has emerged as a recurrently inactivated tumor suppressor in human cancers. Using candidate approaches, recent studies have revealed a synthetic lethal interaction between STAG2 and its paralog STAG1 To systematically probe genetic vulnerabilities in the absence of STAG2, we have performed genome-wide CRISPR screens in isogenic cell lines and identified STAG1 as the most prominent and selective dependency of STAG2-deficient cells ...

    The cohesin subunit STAG2 has emerged as a recurrently inactivated tumor suppressor in human cancers. Using candidate approaches, recent studies have revealed a synthetic lethal interaction between STAG2 and its paralog STAG1 To systematically probe genetic vulnerabilities in the absence of STAG2, we have performed genome-wide CRISPR screens in isogenic cell lines and identified STAG1 as the most prominent and selective dependency of STAG2-deficient cells. Using an inducible degron system, we show that chemical genetic degradation of STAG1 protein results in the loss of sister chromatid cohesion and rapid cell death in STAG2-deficient cells, while sparing STAG2 -wild-type cells. Biochemical assays and X-ray crystallography identify STAG1 regions that interact with the RAD21 subunit of the cohesin complex. STAG1 mutations that abrogate this interaction selectively compromise the viability of STAG2 -deficient cells. Our work highlights the degradation of STAG1 and inhibition of its interaction with RAD21 as promising therapeutic strategies. These findings lay the groundwork for the development of STAG1-directed small molecules to exploit synthetic lethality in STAG2 -mutated tumors.


    Organizational Affiliation

    Boehringer Ingelheim Regional Center Vienna (RCV) GmbH & Co KG, Vienna, Austria mark_paul.petronczki@boehringer-ingelheim.com.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Cohesin subunit SA-1A, C339Homo sapiensMutation(s): 0 
Gene Names: STAG1SA1SCC3
Find proteins for Q8WVM7 (Homo sapiens)
Explore Q8WVM7 
Go to UniProtKB:  Q8WVM7
NIH Common Fund Data Resources
PHAROS  Q8WVM7
Protein Feature View
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence

Find similar proteins by: Sequence  |  Structure

Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Double-strand-break repair protein rad21 homologB, D25Homo sapiensMutation(s): 0 
Gene Names: RAD21HR21KIAA0078NXP1SCC1
Find proteins for O60216 (Homo sapiens)
Explore O60216 
Go to UniProtKB:  O60216
NIH Common Fund Data Resources
PHAROS  O60216
Protein Feature View
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SO4
Query on SO4

Download CCD File 
C
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.37 Å
  • R-Value Free: 0.248 
  • R-Value Work: 0.214 
  • R-Value Observed: 0.215 
  • Space Group: C 2 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 117.077α = 90
b = 151.662β = 90
c = 126.656γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
DIALSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Wellcome TrustUnited Kingdom--

Revision History 

  • Version 1.0: 2019-06-19
    Type: Initial release
  • Version 1.1: 2019-08-21
    Changes: Data collection
  • Version 1.2: 2020-07-01
    Changes: Database references